MXPA05008543A - Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia. - Google Patents
Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia.Info
- Publication number
- MXPA05008543A MXPA05008543A MXPA05008543A MXPA05008543A MXPA05008543A MX PA05008543 A MXPA05008543 A MX PA05008543A MX PA05008543 A MXPA05008543 A MX PA05008543A MX PA05008543 A MXPA05008543 A MX PA05008543A MX PA05008543 A MXPA05008543 A MX PA05008543A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- antitrypsin
- preparation
- fibromyalgia
- medicaments
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invencion se basa en la utilizacion de Alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de fibromialgia, comprendiendo la preparacion de concentrados terapeuticos de Alfa-1 antitripsina, en cualquier forma de administracion tolerable por humanos, procediendo la Alfa-1 antitripsina de purificacion de plasma humano o de produccion por tecnologia recombinante o transgenica con dosis iguales o superiores a 6 mg de Alfa-1 antitripsina por kg de peso corporal durante un periodo de tiempo variable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200402282A ES2281222B1 (es) | 2004-09-24 | 2004-09-24 | Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05008543A true MXPA05008543A (es) | 2006-03-28 |
Family
ID=35875051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05008543A MXPA05008543A (es) | 2004-09-24 | 2005-08-11 | Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7291595B2 (es) |
| EP (1) | EP1656949B1 (es) |
| JP (1) | JP4351663B2 (es) |
| CN (1) | CN100354000C (es) |
| AR (1) | AR054210A1 (es) |
| AU (1) | AU2005203400B2 (es) |
| BR (1) | BRPI0503821B8 (es) |
| CA (1) | CA2514816C (es) |
| DE (1) | DE602005000442T2 (es) |
| ES (2) | ES2281222B1 (es) |
| HK (1) | HK1083601A1 (es) |
| MX (1) | MXPA05008543A (es) |
| NZ (1) | NZ541743A (es) |
| PL (1) | PL1656949T3 (es) |
| PT (1) | PT1656949E (es) |
| UY (1) | UY29056A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8623830B2 (en) * | 2006-09-12 | 2014-01-07 | Beth Israel Deaconess Medical Center, Inc. | Compositions containing α-1-antitrypsin and methods for use |
| US20110237496A1 (en) * | 2008-09-10 | 2011-09-29 | Ilana Nathan | Antinecrotic activity of alpha 1-antitrypsin |
| ES2332645B1 (es) * | 2009-06-30 | 2010-10-18 | Grifols, S.A. | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. |
| BR112015019348A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440679A (en) | 1980-03-05 | 1984-04-03 | Cutter Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
| US5612051A (en) * | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
| US6610324B2 (en) * | 1999-04-07 | 2003-08-26 | The Mclean Hospital Corporation | Flupirtine in the treatment of fibromyalgia and related conditions |
| MXPA02007187A (es) * | 2000-01-25 | 2002-12-09 | Aeropharm Technology Inc | Fromulacion medicinal en aerosol. |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| CA2312109A1 (en) * | 2000-06-23 | 2001-12-23 | Universite De Sherbrooke | Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases |
-
2004
- 2004-09-24 ES ES200402282A patent/ES2281222B1/es not_active Withdrawn - After Issue
-
2005
- 2005-08-02 AU AU2005203400A patent/AU2005203400B2/en not_active Ceased
- 2005-08-04 ES ES05380181T patent/ES2279498T3/es active Active
- 2005-08-04 DE DE602005000442T patent/DE602005000442T2/de active Active
- 2005-08-04 EP EP05380181A patent/EP1656949B1/en active Active
- 2005-08-04 PL PL05380181T patent/PL1656949T3/pl unknown
- 2005-08-04 PT PT05380181T patent/PT1656949E/pt unknown
- 2005-08-08 AR AR20050103296A patent/AR054210A1/es unknown
- 2005-08-08 CA CA2514816A patent/CA2514816C/en not_active Expired - Fee Related
- 2005-08-10 UY UY29056A patent/UY29056A1/es not_active Application Discontinuation
- 2005-08-10 NZ NZ541743A patent/NZ541743A/en not_active IP Right Cessation
- 2005-08-11 MX MXPA05008543A patent/MXPA05008543A/es active IP Right Grant
- 2005-08-29 CN CNB2005100937462A patent/CN100354000C/zh not_active Expired - Fee Related
- 2005-09-08 BR BRPI0503821A patent/BRPI0503821B8/pt not_active IP Right Cessation
- 2005-09-19 US US10/549,759 patent/US7291595B2/en active Active
- 2005-09-20 JP JP2005271471A patent/JP4351663B2/ja not_active Expired - Fee Related
-
2006
- 2006-05-22 HK HK06105870A patent/HK1083601A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0503821A (pt) | 2006-05-09 |
| BRPI0503821B8 (pt) | 2021-05-25 |
| CA2514816C (en) | 2010-12-07 |
| BRPI0503821B1 (pt) | 2018-02-06 |
| US7291595B2 (en) | 2007-11-06 |
| ES2279498T3 (es) | 2007-08-16 |
| ES2281222B1 (es) | 2008-06-01 |
| CN1751739A (zh) | 2006-03-29 |
| PT1656949E (pt) | 2007-04-30 |
| CN100354000C (zh) | 2007-12-12 |
| AU2005203400B2 (en) | 2007-01-18 |
| DE602005000442T2 (de) | 2007-11-15 |
| DE602005000442D1 (de) | 2007-02-22 |
| UY29056A1 (es) | 2006-02-24 |
| CA2514816A1 (en) | 2006-03-24 |
| AR054210A1 (es) | 2007-06-13 |
| HK1083601A1 (en) | 2006-07-07 |
| PL1656949T3 (pl) | 2007-06-29 |
| EP1656949B1 (en) | 2007-01-10 |
| JP4351663B2 (ja) | 2009-10-28 |
| NZ541743A (en) | 2005-12-23 |
| US20060084598A1 (en) | 2006-04-20 |
| AU2005203400A1 (en) | 2006-04-13 |
| EP1656949A1 (en) | 2006-05-17 |
| JP2006089478A (ja) | 2006-04-06 |
| ES2281222A1 (es) | 2007-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004062604A3 (en) | Treatment of cancer with 2-deoxyglucose | |
| MY148108A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| WO2004026303A3 (en) | Use of posaconazole for the treatment of fungal infections | |
| TW200505483A (en) | New medicament compositions based on anticholinergically-effective compounds and β-mimetics | |
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| MY144616A (en) | Substituted dihydroquinazolines | |
| WO2002069945A3 (de) | Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren | |
| WO2008024843A3 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
| IL175259A0 (en) | Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof | |
| PL2392326T3 (pl) | Składnik sylibininowy do leczenia zapalenia wątroby | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| TW200637544A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| MX2013003060A (es) | Terapia de combinacion para tratar infeccion por hcv. | |
| WO2008045378A3 (en) | Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin | |
| TW200724146A (en) | Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant | |
| WO2005082413A3 (en) | Ciclesonide and glycopyrronium combination | |
| MXPA05008543A (es) | Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia. | |
| MXPA03009849A (es) | Uso de azitromicina para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias no infecciosas. | |
| TW200635595A (en) | Medicaments for the treatment of prevention of fibrotic diseases | |
| TW200635574A (en) | Use of a therapeutically effective amount of DHA and ARA in the manufacture of a medicament for the prevention or treatment of respiratory infections in infants | |
| WO2006124573A3 (en) | Treatment of cancer with 2-deoxyglucose | |
| WO2008030853A3 (en) | Combination therapy for human immunodeficiency virus infection | |
| MXPA02009603A (es) | Terapias de dosis divididas con actividad de deterioro vascular. | |
| WO2005058248A3 (en) | A method of treating hiv infection in atazanavir resistant patients using a combination of atazanavir and another protease inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status | ||
| FG | Grant or registration |